AHA 2017 The TNT-POAF study evaluated botulinum toxin as a way to modulate autonomous nervous system tone, to reduce post-operative AF. Time to first episode of AF and the incidence of POAF were numerically lower, but no significant improvements were seen.

AHA 2017 Prof. Clyde Yancy summarizes the most important new recommendations, starting with a new definition of hypertension, the need for a risk conversation and implications for therapy.

AHA 2017 The STEMI-ACCELERATOR 2 program involved multiple types of health professionals in 12 cities across the USA, to develop a treatment plan for STEMI. The program led to a reduction in heart failures and in-house mortality and shorter stays.

AHA 2017 A REVEAL-analysis shows that diabetes status does not affect the effect of anacetrapib on serious coronary events, and that anacetrapib slightly lowers the risk of new onset diabetes.

AHA 2017 New FOURIER analyses show benefit of treatment with evolocumab both in patiënts with PAD, and clinical factors in high-risk post-MI patients can predict extra high risk.

AHA 2017 BRUISE-CONTROL 1 showed an 80% reduction in device pocket hematoma with warfarin continuation vs bridging around device surgery. BRUISE-CONTROL 2 evaluated peri-procedural continuation vs interruption of DOACs.

AHA 2017 Neurotoxin injection yielded numerically lower risk of POAF in TNT-POAF study, along with a shorter duration of first POAF episode, but the study may have been underpowered.

AHA 2017 Analysis of CANVAS program compared use of canagliflozin in primary or secondary prevention and found a greater benefit on CV, renal and death outcomes in those with existing CVD.

AHA 2017 Laura Stevens presented her poster on using artificial intelligence to identify risk factors for CVD and stroke. The found association with coffee was validated with traditional analyses.

AHA 2017 Kyla Lara presented a poster at the AHA on her research on the effect of various dietary patterns, based on Food Frequency Questionnaires, on the risk of developing heart failure.

AHA 2017 An analysis of the EXSCEL trial examined whether risk at baseline predicted the effect of exenatide on mortality and MACE.

AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.